6704.TWO Gwo Xi Stem Cell Applied Technology Co. , Ltd
- Market cap
- TWD 2.12B
- P/E
- -
- P/B
- 2.87x
- ROE
- -13.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6704.TWO undervalued?
Graham numberThe Graham number of Gwo Xi Stem Cell Applied Technology Co. , Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gwo Xi Stem Cell Applied Technology Co. , Ltd fundamental analysis
No fundamental analysis for Gwo Xi Stem Cell Applied Technology Co. , Ltd yet.
Gwo Xi Stem Cell Applied Technology Co. , Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gwo Xi Stem Cell Applied Technology Co. , Ltd
Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-der…
Full company profileGwo Xi Stem Cell Applied Technology Co. , Ltd financial statements
Gwo Xi Stem Cell Applied Technology Co. , Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 177M | 189M | 243M | 181M | 141M | 170M | 187M |
| Gross Profit | 121M | 167M | 197M | 155M | 96.8M | 117M | 132M |
| Operating Income | -83.2M | -74.4M | -99.4M | -115M | -94.0M | -75.9M | -73.7M |
| EBITDA | -59.8M | -44.2M | -60.5M | -49.9M | -16.6M | -13.8M | -12.2M |
| Net Income | -76.9M | -84.2M | -106M | -112M | -88.1M | -83.3M | -80.5M |
| EPS | -1.01 | -0.96 | -1.27 | -1.31 | -0.98 | -0.87 | -0.84 |
| Balance Sheet | |||||||
| Total Assets | 1.06B | 1.18B | 1.09B | 1.04B | 1.23B | 1.06B | 978M |
| Total Liabilities | 466M | 578M | 596M | 535M | 481M | 401M | 398M |
| Shareholders' Equity | 548M | 591M | 482M | 510M | 744M | 661M | 580M |
| Cash & Short-term Investments | 192M | 178M | 119M | 141M | 402M | 283M | 193M |
| Total Debt | 421M | 515M | 545M | 499M | 417M | 364M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -82.9M | -72.6M | -29.1M | -64.2M | -4.87M | -52.3M | -28.0M |
| Capital Expenditure | 225M | 112M | 43.2M | 17.7M | 12.9M | 23.0M | 52.7M |
| Free Cash Flow | -308M | -184M | -72.3M | -81.9M | -17.8M | -75.3M | -80.7M |
| Ratios | |||||||
| ROE | -14.0% | -14.3% | -21.9% | -22.0% | -11.8% | -12.6% | -13.9% |
| ROA | -7.3% | -7.2% | -9.7% | -10.7% | -7.2% | -7.8% | -8.2% |
| Net Profit Margin | -43.5% | -44.7% | -43.5% | -62.1% | -62.4% | -49.0% | -43.1% |
| Debt to Equity | 0.77x | 0.87x | 1.13x | 0.98x | 0.56x | 0.55x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Gwo Xi Stem Cell Applied Technology Co. , Ltd dividends
Gwo Xi Stem Cell Applied Technology Co. , Ltd has not paid dividends in the last 7 fiscal years.
Who owns Gwo Xi Stem Cell Applied Technology Co. , Ltd
Ownership data of Gwo Xi Stem Cell Applied Technology Co. , Ltd is not available yet.
Gwo Xi Stem Cell Applied Technology Co. , Ltd company profile
- Company name
- Gwo Xi Stem Cell Applied Technology Co. , Ltd
- Ticker
- 6704.TWO
- ISIN
- TW0006704000
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 55
- Fiscal year end
- December
- Address
- No. 2, Shengyi 3rd Road, Zhubei, Taiwan, 302041
- Phone
- 886 3 658 5959
- Website
- gwoxi.com.tw
About Gwo Xi Stem Cell Applied Technology Co. , Ltd
Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the treatment of osteoarthritis; and GXIPC1, an allogeneic adipose-derived stem cells therapy in phase I clinical trials for use in the treatment of diabetes. The company was founded in 2011 and is based in Zhubei, Taiwan.
Gwo Xi Stem Cell Applied Technology Co. , Ltd management
3- Chuan-Feng ChiuChief Executive Officer
- Bangyu LIAccounting Supervisor
- Mr. Po-Cheng LinChief Technology Officer